ArticleFrontiers in immunology2025
A dual-modality machine learning precision diagnostic model integrated radiomics and proteomics for breast cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to construct a dual-modal machine learning model that integrates ultrasound radiomics and plasma proteomics for the precise diagnosis of breast cancer. Methods: Using a multi-source data integration strategy, 10 protein markers and 14 ultrasound radiomics features were screened from the TCGA, CPTAC databases, and the clinical cohort (including 60 healthy controls, 60 cases of benign breast diseases, and 60 cases of breast cancer) based on plasma protein mass spectrometry and ultrasound data. A dual-modal diagnostic model was constructed in combination with machine learning algorithms. Results: The results showed that the protein marker detection model performed outstandingly in the primary screening of healthy people and breast diseases (with the highest AUC of 0.974). Still, its diagnostic performance was limited in differentiating benign and malignant diseases (AUC<0.8 under multiple algorithms). The bimodal model demonstrated excellent performance (AUC = 0.938) in differentiating benign and malignant lesions, significantly outperforming the single proteomics model (AUC = 0.830) and the radiomics model (AUC = 0.841). Conclusion: This study confirmed for the synergistic diagnostic value of plasma proteins and ultrasound images, providing a new strategy with both accuracy and accessibility for stratified diagnosis of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.